LIFECORE BIOMEDICAL INC DE
For the period ended May 28, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chaska, State of Minnesota, on March 19, 2024.
| LIFECORE BIOMEDICAL, INC. | |
| By: | /s/ John D. Morberg |
| John D. Morberg | |
| Executive Vice-President, Chief Financial Officer and Secretary(Principal Financial and Accounting Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints James G. Hall and John D. Morberg, and each of them, as his or her attorney-in-fact, with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorney-in-fact to any and all amendments to said Report on Form 10-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ James G. Hall | ||
| James G. Hall | President and Chief Executive Officer (Principal Executive Officer) and Director | March 19, 2024 |
| /s/ John D. Morberg | ||
| John D. Morberg | Executive Vice-President, Chief Financial Officer and Secretary (Principal Financial Officer and Principal Accounting Officer) | March 19, 2024 |
| /s/ Craig A. Barbarosh | ||
| Craig A. Barbarosh | Director | March 19, 2024 |
| /s/ Nathaniel Calloway | ||
| Nathaniel Calloway | Director | March 19, 2024 |
| /s/ Raymond Diradoorian | ||
| Raymond Diradoorian | Director | March 19, 2024 |
| /s/ Jeffrey L. Edwards | ||
| Jeffrey L. Edwards | Director | March 19, 2024 |
| /s/ Katrina L. Houde | ||
| Katrina L. Houde | Director | March 19, 2024 |
| /s/ Christopher Kiper | ||
| Christopher Kiper | Director | March 19, 2024 |
| /s/ Nelson Obus | ||
| Nelson Obus | Director | March 19, 2024 |
| /s/ Joshua E. Schechter | ||
| Joshua E. Schechter | Director | March 19, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.